Listeria-based hepatocellular carcinoma vaccine facilitates anti-PD-1 therapy by regulating macrophage polarization
G Xu, D Feng, Y Yao, P Li, H Sun, H Yang, C Li… - Oncogene, 2020 - nature.com
Recently, patients with advanced cancers have been benefited greatly from immune
checkpoint blockade immunotherapy. However, immune checkpoint blockade is still …
checkpoint blockade immunotherapy. However, immune checkpoint blockade is still …
Emerging trends in the immunotherapy of pancreatic cancer
Pancreatic cancer (PC) is the fourth leading cause of cancer-related deaths in the US,
claiming approximately 43,000 lives every year. Much like other solid tumors, PC evades the …
claiming approximately 43,000 lives every year. Much like other solid tumors, PC evades the …
Immunotherapy with a HER2-Targeting Listeria Induces HER2-Specific Immunity and Demonstrates Potential Therapeutic Effects in a Phase I Trial in Canine …
NJ Mason, JS Gnanandarajah, JB Engiles, F Gray… - Clinical Cancer …, 2016 - AACR
Abstract Purpose: Recombinant Listeria vaccines induce tumor-specific T-cell responses
that eliminate established tumors and prevent metastatic disease in murine cancer models …
that eliminate established tumors and prevent metastatic disease in murine cancer models …
Administration of gemcitabine after pancreatic tumor resection in mice induces an antitumor immune response mediated by natural killer cells
E Gürlevik, B Fleischmann-Mundt, J Brooks, IE Demir… - Gastroenterology, 2016 - Elsevier
Background & Aims Even after potentially curative R0 resection, patients with pancreatic
ductal adenocarcinoma (PDAC) have a poor prognosis owing to high rates of local …
ductal adenocarcinoma (PDAC) have a poor prognosis owing to high rates of local …
Entinostat converts immune-resistant breast and pancreatic cancers into checkpoint-responsive tumors by reprogramming tumor-infiltrating MDSCs
BJ Christmas, CI Rafie, AC Hopkins, BA Scott… - Cancer immunology …, 2018 - AACR
Immune-checkpoint inhibition (ICI) has revolutionized treatment in cancers that are naturally
immunogenic by enabling infiltration of T cells into the tumor microenvironment (TME) and …
immunogenic by enabling infiltration of T cells into the tumor microenvironment (TME) and …
Pancreatic cancer-targeting exosomes for enhancing immunotherapy and reprogramming tumor microenvironment
W Zhou, Y Zhou, X Chen, T Ning, H Chen, Q Guo… - Biomaterials, 2021 - Elsevier
Immunotherapy has gained increasing focus in treating pancreatic ductal adenocarcinoma
(PDAC), since conventional therapies like chemotherapy could not provide satisfactory …
(PDAC), since conventional therapies like chemotherapy could not provide satisfactory …
Engineered Lactococcus lactis secreting Flt3L and OX40 ligand for in situ vaccination-based cancer immunotherapy
J Zhu, Y Ke, Q Liu, J Yang, F Liu, R Xu, H Zhou… - Nature …, 2022 - nature.com
In situ vaccination is a promising strategy to convert the immunosuppressive tumor
microenvironment into an immunostimulatory one with limited systemic exposure and side …
microenvironment into an immunostimulatory one with limited systemic exposure and side …
Nanocarrier co-formulation for delivery of a TLR7 agonist plus an immunogenic cell death stimulus triggers effective pancreatic cancer chemo-immunotherapy
Although toll-like receptor (TLR) agonists hold great promise as immune modulators for
reprogramming the suppressive immune landscape in pancreatic ductal adenocarcinoma …
reprogramming the suppressive immune landscape in pancreatic ductal adenocarcinoma …
A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety …
Abstract Purpose: Listeria monocytogenes (Lm)-based vaccines stimulate both innate and
adaptive immunity. ANZ-100 is a live-attenuated Lm strain (Lm Δ actA/Δ inlB). Uptake by …
adaptive immunity. ANZ-100 is a live-attenuated Lm strain (Lm Δ actA/Δ inlB). Uptake by …
An ISCOM vaccine combined with a TLR9 agonist breaks immune evasion mediated by regulatory T cells in an orthotopic model of pancreatic carcinoma
C Jacobs, P Duewell, K Heckelsmiller… - … Journal of Cancer, 2011 - Wiley Online Library
Vaccines based on immune stimulatory complexes (ISCOM) induce T‐cell responses
against tumor antigen (Ag). However, immune responses are impaired in pancreatic cancer …
against tumor antigen (Ag). However, immune responses are impaired in pancreatic cancer …